Johnson & Johnson beats Q4 forecasts as drug sales shine
Jan 21 (Reuters) - Johnson & Johnson reported quarterly results that came in above Wall Street estimates on sharply higher sales of its prescription drugs and improving sales of its medical devices.
The diversified healthcare company said on Tuesday it earned $3.52 billion, or $1.23 per share, in the fourth quarter. That compared with $2.57 billion, or 91 cents per share, in the year-earlier period, when J&J took a charge of $800 million related mostly to recalls of defective "metal-on-metal" hip replacement devices.
Excluding special items, J&J earned $1.24 per share. Analysts, on average, expected $1.20 per share, according to Thomson Reuters I/B/E/S.
- Islamic State executes soldiers, takes hostages at Syria base: social media |
- Breakthrough hopes dented as Ukraine accuses Russia of new incursion |
- Gaza truce holding but Israel's Netanyahu under fire at home |
- WHO shuts Sierra Leone lab after worker infected with Ebola
- Ukraine warns Europe of Russian gas cut-off, Moscow denies